THANK YOU to our study participants, study partners, and researchers that contributed to this FDA drug approval. We're proud to have been a top enrolling site in the pivotal Kisunla trials, with and to have passed a two-week on-site FDA audit of our work with no findings. We're continuing to enroll study participants in the search for more effective and safe treatments being evaluated for the prevention and treatment of Alzheimer's. In particular, we're now expanding our reach in diverse communities that have been underrepresented across Alzheimer's research.
About us
Irvine Clinical Research is an independent, physician investigator-owned clinic specializing in Phase 2-3 sponsored clinical trials in neurology and psychiatry. We have a demonstrated history of enrolling subjects quickly, producing quality data to Sponsors, and ensuring the highest standard of patient care. Our largest areas of study are in Mild Cognitive Impairment/Early Alzheimer's Disease and Depression therapeutic trials. According to publicly available CMS data, Irvine Clinical Research is the top independent site in Alzheimer’s Disease clinical trials in the state of California, as measured by industry research grants.
- Website
-
https://irvineclinical.com/
External link for Irvine Clinical Research
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Irvine, CA
- Type
- Privately Held
- Founded
- 1978
- Specialties
- Clinical Research, Clinical Trials, Medical, Neuropsychiatry, Neurology, Psychiatry, and Alzheimer's Disease
Locations
-
Primary
Get directions
2515 McCabe Way
Suite 350
Irvine, CA 92614, US
Employees at Irvine Clinical Research
Updates
-
Thank you to CTAD Clinical Trials on Alzheimer's Disease for organizing our favorite meeting of the year again, this year in Boston. It was great to see more positive results of our work with lecanemab, donanemab, and other clinical programs that our doctors and participants helped make happen. Our team also shared data on prescreening for the RBANS in AD trials and recruiting underrepresented minorities. With the first disease-modifying therapy fully FDA-approved, we still have a lot of work to do to find effective and safe medications for the treatment and prevention of Alzheimer's Disease.
-
-
Happy to partner with Justin Ford and Global Alzheimer's Platform Foundation to recruit more diverse participants into our clinical trials on Alzheimer's Disease. We are delighted by recent successful trial results, but there is more work to do to find more effective and safe options for patients with memory concerns.
Eisai and Biogen announced successful results in its Phase 3 clinical trial of the drug lecanamab. The drug delayed progression of cognitive loss in a double-blind, placebo-controlled, randomized drug trial by 27%. The study was based on 1,795 patients, 25 percent of whom in the US were Hispanic and African American. I’m so honored to have the opportunity to visit and partner with Irvine Clinical Research one of the sites part of this landmark trial. They are certain this will open new pathways for future research and a cure for Alzheimer's Disease!
-